Oct. 7 at 12:04 AM
$AVXL Last Thursday AVXL’s share price rose to a high of
$9.65 as a result of the two 3-71 schizophrenia PRs. Therefore the current share price,
$9.61, seems appropriate for the market conditions.
If Blarcamesine is recommended by the CHMP for marketing in Europe, I anticipate the SP will hit a new all time high (over
$28.86).
FYI - The last company I owned the stock of, which was acquired, did not announce the acquisition until about a year after their first and only drug was approved for marketing by the FDA. That company’s stock rose from the PDUFA day’s price of about
$15/sh to
$105/sh when their acquisition was announced.
